Union Minister Inaugurates Advanced Diagnostic and Interventional Cardiac Manufacturing Facilities, Marking India’s Accelerating Transition from Medical Device Importer to Global Healthcare Technology Supplier
On November 15, 2025, PiyushGoyal, Union Minister of Commerce and Industry, visited the Andhra Pradesh MedTech Zone (AMTZ) in Visakhapatnam to inaugurate two transformative medical technology manufacturing facilities—the 3i MedTech MRI production line and the Innovation Imaging Technologies Pvt. Ltd. (IITPL) catheterization laboratory (Cathlab) manufacturing plant. The inauguration symbolized a decisive inflection point in India’s healthcare manufacturing trajectory, moving beyond episodic policy announcements toward tangible, operational sovereignty in advanced medical device production—technology categories that have historically symbolized India’s technological dependence on multinational corporations dominating global healthcare markets.
The Andhra Pradesh MedTech Zone, established in 2016 across 270 acres in Visakhapatnam adjacent to the Visakhapatnam Steel Plant, represents one of the world’s most comprehensive single-site medical device manufacturing ecosystems. The campus houses over 150 manufacturing companies, collectively engaged in research, development, and production spanning the entire medical device spectrum—from basic consumables (masks, syringes, gloves) to advanced imaging systems (MRI machines, CT scanners) and complex therapeutic devices (pacemakers, cyclotrons, cardiac catheters).
AMTZ’s defining institutional characteristic is its integrated common facility infrastructure. Rather than requiring each manufacturer to invest independently in capital-intensive scientific testing and certification equipment, AMTZ provides shared access to specialized facilities designed specifically for medical device production. These include electromagnetic compatibility (EMC) testing through the ELECTRA Centre (operated by TÜV Rheinland in partnership with AMTZ), gamma irradiation sterilization through the COBALTA facility, component testing laboratories, advanced moldingcenters (cabinet, vacuum, and injection molding), 3D design and printing capabilities, and comprehensive sterilization and toxicity evaluation services. Quantitatively, this shared-facility architecture reduces manufacturing costs for individual companies by 40-50% compared to independent facility development, directly improving product affordability and international competitiveness.
The zone’s institutional distinction transcends manufacturing infrastructure. AMTZ uniquely functions as the only medical technology cluster globally to simultaneously host three distinct international institutional presences: a World Trade Center (WTC-AMTZ), a WHO Collaborating Centre for Health Innovation, and the Centre of Excellence for Medical Technology for BRICS countries. The WTC license, awarded by the World Trade Centers Association headquartered in New York, connects AMTZ directly to 392 World Trade Centers across 100 countries, establishing structured trade pathways and investment linkages. The WHO Collaborating Centre status, formalized through the Kalam Institute of Health Technology (KIHT), positions AMTZ within the World Health Organization’s global network for innovation scaling and standardization development. These three institutional elements collectively transform AMTZ from a manufacturing cluster into an integrated node within global healthcare governance and trade architecture.
3i MedTech
Magnetic Resonance Imaging (MRI) technology represents a paradigmatic case study of India’s historical medical device import dependence. Globally, MRI manufacturing remains concentrated among a limited number of multinational corporations: General Electric, Siemens AG (Germany), and Philips (Netherlands) collectively control approximately 60-70% of installed MRI systems in Indian hospitals. This oligopolistic market structure produces profound economic consequences throughout the Indian healthcare system.
A new 1.5 Tesla MRI system—the diagnostic standard for comprehensive neurological, musculoskeletal, and vascular imaging—commands purchase prices of approximately ₹12-18 crores when sourced from established foreign manufacturers through direct procurement channels. Beyond capital acquisition costs, total cost of ownership calculations must account for: installation and facility adaptation (₹50-75 lakhs), annual service contracts (₹40-60 lakhs annually), supply chain costs for specialized cryogenic materials (liquid helium), routine maintenance labor, and replacement parts sourcing through authorized service networks often priced at premiums reflecting geographic distance and logistical complexity. Over a 10-year ownership lifecycle, aggregate costs frequently exceed ₹35-45 crores for metropolitan hospitals and substantially exceed revenue generation capacity for secondary and tertiary hospitals in tier-2 and tier-3 cities. This cost structure fundamentally restricts MRI availability to approximately 500-600 installed systems across India’s 28 states and 8 union territories—a penetration rate of approximately 0.04 MRI systems per million population, compared to global standards exceeding 5-8 systems per million population in developed economies.
The operational consequence is diagnostic bottlenecking. Patients requiring MRI imaging for complex neurological conditions (suspected cerebral aneurysms, multiple sclerosis, spinal cord compression), musculoskeletal pathology (anterior cruciate ligament tears, degenerative disc disease), and vascular assessments frequently encounter waiting periods exceeding 4-6 weeks in metropolitan centers and months in secondary cities. This delay translates into deferred diagnosis and therapeutic intervention initiation, measurably worsening clinical outcomes in time-sensitive pathologies. Rural populations routinely lack local MRI availability, necessitating travel—frequently economically prohibitive given out-of-pocket healthcare financing patterns in India where 48% of healthcare expenditure derives from individual patient payments rather than insurance or government subsidies.
3i MedTech’s Technological Response: The company, operating under the Refex Group corporate umbrella, established an indigenous manufacturing line at AMTZ with the explicit mandate of producing advanced 1.5 Tesla superconducting MRI systems under the brand designation “Anamaya” (Sanskrit: “health”). The system incorporates superconducting magnet technology utilizing 1.5 Tesla magnetic field strength—established as the clinical standard for diagnostic imaging across neurology, oncology, and vascular medicine—delivered through helium-cooled superconducting magnet assemblies meeting international specifications for field homogeneity, stability, and safety performance.
The technical specifications of Anamaya align with international diagnostic MRI standards: 1.5T superconducting magnet with active shielding architecture, 70-centimeter patient bore diameter with flared opening design reducing claustrophobia-induced patient anxiety, gradient systems delivering 33 millitesla per meter peak amplitude with 200 tesla/meter per second slew rates supporting high-speed pulse sequences, digital radiofrequency systems with minimum 32 independent receiver channels enabling multi-parametric mapping protocols (T1, T2, FLAIR, diffusion-weighted imaging), and comprehensive safety features including emergency magnet ramp-down capabilities (quench protection systems limiting discharges to <3 minutes). The system achieves faster scan times relative to imported equipment through optimized pulse sequences and signal processing algorithms, paired with noise reduction technologies delivering scanning environments <80 decibels—permitting auditory communication during procedures and reducing patient anxiety compared to conventional MRI systems operating at 100-110+ decibels.
Economic Impact and Market Transformation: The introduction of indigenous MRI manufacturing addresses the core constraint limiting MRI accessibility—capital cost. Manufacturing cost structures for indigenously-produced MRI systems are estimated at 30-40% below equivalent imported systems when accounting for elimination of international shipping, customs duties, currency exchange premiums, and multinational corporate profit margins. This cost differential directly translates to reduced equipment acquisition expense for hospitals, enabling secondary and tertiary facilities to incorporate MRI services previously economically infeasible.
The first commercial installation of an Anamaya system occurred at Ruby Hall Clinic’s facility in Sangamner (Maharashtra) in November 2024, establishing proof-of-concept for both manufacturing viability and clinical acceptance. Subsequent installations target secondary city medical institutions, district hospitals, and emerging private diagnostic networks in tier-2 and tier-3 metropolitan areas. By expanding MRI availability beyond metropolitan concentration, indigenous manufacturing addresses documented diagnostic inequality where urban patients in major metros receive MRI-based diagnoses within weeks while secondary city patients experience delays exceeding 8-12 weeks or face travel expenses exceeding hospital costs in their home regions.
IITPL Catheterization Laboratory Manufacturing: Interventional Cardiology Decentralization
Catheterization laboratories—specialized cardiac imaging suites integrating fluoroscopic X-ray systems with hemodynamic monitoring, contrast injection mechanisms, and therapeutic device delivery platforms—constitute essential infrastructure for interventional cardiology procedures (percutaneous coronary intervention, angioplasty, stent insertion, coronary angiography). These facilities are simultaneously critical diagnostic instruments and therapeutic platforms, enabling both identification of coronary artery disease and real-time therapeutic intervention through minimally invasive vascular catheter techniques.
The Access-Equity Challenge in Cardiac Care: Approximately 2.5 million Indians die annually from cardiovascular disease—the leading cause of mortality accounting for approximately 28% of total national mortality. Concurrently, cardiovascular disease burden is shifting from traditional metropolitan concentration toward tier-2 and tier-3 cities, where diagnostic and therapeutic infrastructure remains severely underdeveloped. Data from 2024-25 indicate that tier-2 and tier-3 cities collectively account for 45-50% of cardiovascular disease mortality despite possessing <15% of installed catheterization laboratory infrastructure. This geographic-infrastructure mismatch creates systematic treatment delays—patients in secondary cities frequently require travel of 200-500 kilometers to access catheterization-based intervention, frequently arriving days following acute myocardial infarction when therapeutic intervention windows have closed and myocardial necrosis has progressed beyond recovery potential.
Traditional catheterization laboratory infrastructure reflects a capital-intensive model designed for metropolitan tertiary centers. Standard equipment configurations from established manufacturers (Philips, GE, Siemens) command acquisition costs of ₹8-15 crores per facility, generating total cost-of-ownership burdens comparable to or exceeding MRI systems. This economic barrier restricts catheterization laboratory installation to approximately 1,800-2,000 operational units across India, concentrated within metropolitan areas and affluent private hospital networks. India currently achieves approximately 0.2 interventional procedures per 1,000 population annually—substantially below WHO-recommended thresholds of 1-2 procedures per 1,000 population required to address disease burden comprehensively.
IITPL’s Innovative Response: Innovation Imaging Technologies Pvt. Ltd. (IITPL), operating as a joint venture between VJ Technologies (New York), Ex-Alpha X-ray Promoters (Germany), and Innvolution Healthcare (New Delhi), established manufacturing capability for indigenous catheterization laboratory systems under the “Pinnacle” product brand family. The company achieved commercial scale within 3 years of founding—an accelerated timeline reflecting focused execution on core manufacturing disciplines rather than comprehensive parallel technology development.
IITPL’s Cathlab designs feature: 100-kilowatt high-frequency X-ray generators providing fluoroscopic imaging capability with digital subtraction angiography, flat-panel imaging detectors with 20-inch field-of-view optimizing coronary and structural cardiac visualization, dynamic gantry systems enabling +/- 120 degrees left-anterior-oblique/right-anterior-oblique movement and +/- 55 degrees cranio-caudal positioning for complex anatomical access, integrated stent enhancement software providing real-time visualization optimization during percutaneous coronary intervention, and sophisticated patient safety systems including anticollision mechanisms and dual-level radiation shielding. The system achieves cost positioning approximately 40-50% below equivalent imported systems while maintaining clinical performance specifications aligned with international standards.
Scaling Access and Geographic Equity: IITPL’s strategic objective involves installation of indigenous catheterization laboratories across India’s 718 districts by 2030—an expansion from current ~250 district-level Cathlabs to comprehensive national coverage. This district-level distribution would enable local interventional cardiology services, dramatically reducing patient travel burden and enabling rapid response to acute coronary syndromes within therapeutic intervention windows. The affordability differential permits secondary city hospitals and district medical centers to incorporate catheterization services previously economically infeasible, directly addressing documented healthcare equity gaps between metropolitan and secondary city populations.
By November 2025, IITPL maintained operational presence across 67 cities spanning 16 Indian states. Recent expansion into AMTZ manufacturing capacity (formalized through Minister Goyal’s November 2025 inauguration) enables scaled production meeting anticipated demand from tier-2/tier-3 healthcare expansion initiatives.
Trade Deficit Correction & Import Substitution Economics
India currently imports 70-80% of high-end medical devices, generating an estimated annual import bill exceeding USD 7 billion (approximately ₹58,000 crores at prevailing exchange rates). This import concentration reflects structural barriers: India manufactures approximately 15% of domestically consumed MRI systems, <20% of advanced CT scanners, <10% of robotic surgical systems, and minimal capacity in high-end implants and therapeutic devices. The import-export imbalance reflects asymmetric market structure where multinational corporations export sophisticated devices to India while importing only low-value consumables (syringes, gloves, basic diagnostic kits).
Import Substitution Impact: The 3i MedTech and IITPL manufacturing facilities represent early-stage import substitution within high-value device categories. Quantitative projections estimate that full-scale production ramping would substitute domestically-produced MRI systems for approximately 30-40% of India’s annual MRI installations (projected at 150-200 units annually by 2028), reducing annual MRI import expenditure by approximately USD 200-300 million. Similarly, scaled Cathlab production could substitute indigenous manufacturing for 50-60% of anticipated installations, reducing Cathlab import costs by USD 150-200 million annually.
Aggregate import substitution through AMTZ-coordinated manufacturing initiatives targeting MRI, Cathlab, CT scanning, ultrasound, robotic surgical systems, implants, and diagnostic equipment could reduce India’s medical device import bill from current USD 7 billion to approximately USD 4-4.5 billion within 8-10 years—a reduction of 35-40% representing capital savings of USD 2.5-3 billion annually. These savings directly reduce healthcare costs for hospitals and ultimately patient treatment expenditures, improving accessibility within India’s price-sensitive healthcare market.
Strategic Memoranda and Ecosystem Expansion
The November 15, 2025, ministerial visit catalyzed multiple strategic collaborations through signed memoranda of understanding, formalized through PiyushGoyal’s presence. Notable partnerships included:
MoU between AMTZ and the Artificial Limb Centre/National Institute for the Empowerment of Persons with Intellectual Disability (NIEPID) establishing coordinated manufacturing of assistive devices and rehabilitation technology—extending AMTZ capability beyond diagnostic and therapeutic devices into assistive and preventive technology domains.
MoU between the World Trade Center AMTZ and PoonawallaFincorp establishing specialized financial instruments for AMTZ-based manufacturers targeting IPO readiness and growth-stage capital structuring. This directly addresses documented capital constraints limiting expansion of successful medical device manufacturers.
Collaborations between the Kalam Institute of Health Technology (KIHT) and the Indian Institute of Materials Management (IIMM) establishing supply chain formalization and logistics capability development across AMTZ ecosystem participants—addressing operational constraints beyond device manufacturing into distribution infrastructure.
International Trade Integration
The symbolic “Varex Detector export” flag-off ceremony during Minister Goyal’s visit marked Indian medical device export capability maturation. Varex (previously known as ViaSat Technologies) produces X-ray detector components—fundamental subsystems for diagnostic imaging equipment. The export of Varex detectors to international markets indicates that AMTZ-based manufacturers have progressed beyond domestic-only production toward integrated global supply chains, supplying components to international equipment manufacturers and establishing India as a component supplier within global medical device value chains.
This export capability reflects broader ecosystem maturation. Data indicate Indian medical device exports have reached USD 4 billion annually (as of 2024-25), with projections targeting USD 5-6 billion by 2030. AMTZ-based manufacturers contribute an estimated 15-20% of national medical device exports, with particularly high proportions in specific categories (orthopedic devices, diagnostic kits, implants).
Governance and WHO Recognition
The WHO Collaborating Centre designation carries significance beyond institutional prestige. The collaboration establishes formal mechanisms through which AMTZ-manufactured devices undergo international quality validation and standardization processes aligned with World Health Organization technical specifications. This positioning enables direct market access for AMTZ-manufactured products within developing countries following WHO procurement frameworks, particularly through GAVI, the Vaccine Alliance and Global Fund procurement mechanisms that supply healthcare commodities to low-income countries. These institutional procurement channels provide stable demand pathways for affordably-priced medical devices, enabling volume-based revenue models supporting manufacturing scale-up.
Broader National Context and Strategic Implications
The AMTZ inaugurations must be contextualized within India’s comprehensive medical device policy evolution. The Production Linked Incentive (PLI) scheme for medical devices, operationalized in 2021, has mobilized investment in 19 greenfield manufacturing projects targeting high-end device categories previously entirely imported. Approved PLI beneficiaries include manufacturers targeting linear accelerators (radiotherapy systems), advanced imaging (MRI, CT, ultrasound), surgical robotics, and specialized implants. By November 2025, approximately ₹5,000-6,000 crores of private capital had been deployed toward PLI-backed projects, with government incentives reaching approximately ₹1,200-1,500 crores. These combined private and public investments create momentum toward measurable import substitution within 5-7 years.
Institutional Maturation of Medical Device Sovereignty
The 3i MedTech and IITPL facilities represent institutional crystallization of India’s multi-year medical device import substitution strategy. By combining: technological capability development (indigenous MRI, Cathlab design and manufacturing), shared infrastructure provisioning (AMTZ common facilities), international institutional positioning (WHO Collaborating Centre, World Trade Center), financial mechanisms (specialized medical device funding), and deliberate export pathway development, India has progressed from aspirational policy toward operational implementation.
The aggregate impact—measured across affordability (30-50% cost reduction for advanced devices), accessibility (expanded geographic distribution of MRI and catheterization services), trade deficit mitigation (USD 2.5-3 billion annual import substitution potential), and strategic autonomy (reduced dependence on multinational device manufacturers for critical healthcare infrastructure)—positions India toward a credible pathway toward healthcare manufacturing self-reliance by 2035.
However, complete import substitution remains contingent on sustained investment in component manufacturing ecosystems (specialized magnet production, advanced electronics, precision optics), regulatory framework harmonization with international standards, and explicit government procurement policies prioritizing domestic devices where clinical equivalence is established. The November 2025 ministerial visits signal political commitment to these enabling conditions, though execution risk remains material across multiple implementation dimensions.
- KandulaHasaan
